Challenges in Pulmonary and Critical Care: 2018
|
|
- Marilynn Lewis
- 5 years ago
- Views:
Transcription
1 Challenges in Pulmonary and Critical Care: 2018 Interstitial Lung Disease: Evolving Our Understanding of a Deadly Disease 1 Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical Care Medicine University of Michigan Ann Arbor, MI 2 Disclosures Kevin Flaherty, MD, MS serves as a consultant for Boehringer Ingelheim, Veracyte, Roche/Genentech, FibroGen, and Sanofi Genzyme. 3 1
2 Learning Objectives 1. Explain the importance of early identification and differentiation of interstitial lung disease (ILDs). 2. Describe the diagnostic approach for ILD, and when to refer patients to ILD centers. 3. Discuss the management of idiopathic pulmonary fibrosis (IPF), including its risk factors and comorbidities. 4. Recognize the role of patient education for effective management of ILD. 4 PRE-TEST QUESTIONS 5 Pre-I1: On average how much time is estimated to elapse between onset of symptoms and correct diagnosis: 1. 6 months years years Pre-test ARS Question 1 4. More than 5 years 6 2
3 Pre-test ARS Question 2 Pre-I2: Each of the following diagnostic tests should typically be performed in the evaluation of patients with suspected ILD except: 1. Complete history and physical exam 2. Complete pulmonary function testing including pulmonary mechanics and diffusion capacity for carbon monoxide 3. High resolution CT of the chest 4. Video assisted surgical lung biopsy 7 Pre-test ARS Question 3 Pre-I3: A 64 year old male with newly diagnosed IPF returns to clinic to discuss possible therapy. Which of the following choices would be most likely to slow the decline in his lung function (FVC)? 1. Prednisone/azathioprine/N-acetyl cysteine 2. Pirfenidone or nintedanib 3. Warfarin 4. N-acetyl cysteine 5. Imatanib 8 Pre-test ARS Question 4 Pre-I4: Each of the following co-morbidities are common with IPF except: 1. Cardiovascular disease 2. Gastroesophageal reflux disease 3. Obstructive sleep apnea/sleep disorders 4. Asthma 5. Pulmonary hypertension 9 3
4 Pre-test ARS Question 5 Pre-I5: How confident are you in your ability to educate patients with ILD on the most effective strategies to improve their outcomes? 1. Not at all confident 2. Not very confident 3. Somewhat confident 4. Pretty much confident 5. Very confident 10 Interstitial Lung Diseases - Difficulties Diverse group of disorders (130+) Similar symptoms, physiology, radiology Difficult nomenclature Limited, often toxic, treatments 11 Interstitial Lung Diseases - Difficulties Diverse group of disorders (130+) Similar symptoms, physiology, radiology Difficult nomenclature Limited, often toxic, treatments 12 4
5 Path to Diagnosis is Often Long and Tortuous Symptom Onset Often 1-2 years Diagnosis Patients are often misdiagnosed with bronchitis, asthma, COPD, emphysema, or heart disease as symptoms are common manifestations of many diseases Early and accurate diagnosis allows timely initiation of appropriate therapy 13 Distinguishing Dyspnea: IPF Prevalence COPD: chronic obstructive pulmonary disease; IPF: idiopathic pulmonary fibrosis. 1. Raghu G et al. Resp Crit Care Med. 2006;174: Go AS et al. Circulation. 2013;127:e6-e Wheaton AG et al. MMWR Morb Mortal Wkly Rep. 2015;64: When to Suspect ILD History Chronic exertional dyspnea Chronic cough without purulence Fatigue Physical Examination Bilateral velcro-like crackles Clubbing/acrocyanosis Physiologic Findings Low DLCO Resting/exertional desaturation Normal/Reduced FVC Chest Radiograph Nonspecific changes/bilateral basal reticular infiltrates 15 Lederer & Martinez N Engl J Med 2018:378:
6 Diffuse Parenchymal Lung Disease (DPLD) DPLD of known cause, eg, Idiopathic Granulomatous Other forms of drugs or association, eg, Interstitial DPLD, eg, DPLD, eg, LAM, HX, collagen vascular disease Pneumonias sarcoidosis etc Major Rare Unclassifiable Idiopathic Pulmonary Fibrosis Lymphoid Interstitial Pneumonia Nonspecific interstitial pneumonia (idiopathic) Pleuroparenchymal Fibroelastosis Acute Interstitial Pneumonia Respiratory bronchiolitis interstitial lung disease Desquamative Interstitial Pneumonia Cryptogenic Organizing Pneumonia ATS/ERS Consensus Statement. Am J Respir Crit Care Med. 2002;165: Travis et al., Am J Resp Crit Care Med 2013; 188(6): Idiopathic Pulmonary Fibrosis IPF is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause. It occurs primarily in older adults, is limited to the lungs, and is defined by the histopathologic and/or radiologic pattern of Usual Interstitial Pneumonia 17 Raghu et al., ATS/ERSJ/RS/ALAT Consensus Statement. Am J Respir Crit Care Med. 2018: 198:5 IPF - Pathobiology 18 Aryal & Nathen Expert Opinion Emerging Drugs 2018;23:
7 Interstitial Lung Disease Diagnostic Team Clinician Radiologist Pathologist Communication among multidisciplinary team members is essential for an accurate diagnosis 19 Putting the Pattern in Context Usual Interstitial Pneumonia (UIP) Idiopathic Pulmonary Fibrosis (IPF) Nonspecific Interstitial Pneumonia (NSIP) Idiopathic Organizing Pneumonia Idiopathic COP/BOOP Rheumatoid Lung Chronic Exposures -Hypersensitivity pneumonia -Occupational -Connective Tissue Disease - Hypersensitivity Pneumonia OP due to: - a very long list ATS/ERS/JRS/ALAT Diagnostic Criteria for IPF Exclusion of known causes of Interstitial Lung Disease (ILD)* AND Pattern of UIP on HRCT and/or histopathology *Environmental exposures Connective tissue disease Drug toxicity etc. Diagnosis of IPF can be made in MDT setting after considering clinical, HRCT and histopathology 21 Raghu et al., ATS/ERSJ/RS/ALAT Consensus Statement. Am J Respir Crit Care Med. 2018: 198:5 7
8 HRCT Patterns of UIP 2018 Guidelines 22 Raghu et al., ATS/ERSJ/RS/ALAT Consensus Statement. Am J Respir Crit Care Med. 2018: 198:5 HRCT Patterns of UIP 2018 Guidelines UIP Subpleural & basal predominant; distribution often heterogeneous Honeycombing +/-peripheral traction bronchiectasis or bronchiolectasis Raghu et al., ATS/ERSJ/RS/ALAT Consensus Statement. Am J Respir Crit Care Med. 2018: 198:5 23 HRCT Patterns of UIP 2018 Guidelines Probable UIP Subpleural & basal predominant; distribution often heterogeneous Reticular pattern with peripheral traction bronchiectasis or bronchiolectasis May have mild ground glass opacification Raghu et al., ATS/ERSJ/RS/ALAT Consensus Statement. Am J Respir Crit Care Med. 2018: 198:5 24 8
9 HRCT Patterns of UIP 2018 Guidelines Indeterminate for UIP Subpleural & basal predominant Subtle reticulation May have mild GGO or distortion (early UIP pattern) CT features and/or distribution of lung fibrosis that do not suggest any specific etiology (truly indeterminate) Raghu et al., ATS/ERSJ/RS/ALAT Consensus Statement. Am J Respir Crit Care Med. 2018: 198:5 25 HRCT Patterns of UIP 2018 Guidelines Alternative Diagnosis Features suggest another diagnosis CT Features: Cysts Marked mosaic attenuation Predominant GGO Profuse micronodules Centrilobular nodules Nodules Consolidation Predominant distribution: Peribronchovascular Perilymphatic Upper or mid-lung Other: Pleural plaques (consider asbestosis) Dilated esophagus (consider CTD) Distal clavicular erosions (consider RA) Extensive lymph node enlargement Pleural effusions, pleural thickening (consider CTD/drugs) Raghu et al., ATS/ERSJ/RS/ALAT Consensus Statement. Am J Respir Crit Care Med. 2018: 198:5 26 HRCT Machine Learning Deep learning algorithm to classify HRCT into UIP, possible UIP or inconsistent with UIP 1157 HRCT scans (929 training set, 89 validation, 139 Test A) 150 HRCT scans from separate study Test B with 91 thoracic radiologist interpretations RESULTS Test A 76 % accuracy with 93% within one category Test B Thoracic radiologist 71% accurate Test B Machine 73% accurate (better than 60/91, 66% radiologists) Weighted kappa Radiologist 0.67, Machine/Radiologist 0.69 Similar results using Fleischner HRCT criteria 27 Walsh et al, Lancet Resp Med Sept
10 HRCT Machine Learning Similar prognostic separation for UIP pattern assigned by majority radiology opinion or machine Algorithm 28 Walsh et al, Lancet Resp Med Sept 2018 Probability of IPF Increases with Advancing Age and Increased Fibrosis on HRCT OR per 5-year age increment Odds Ratio per 5-year increase in age Age (Yrs) IPF Probability at least 80% (specificity 96%) when: - Age over 60 and - Reticulation on HRCT at least ~30% 29 Salisbury ML, et al. Respir Med. 2016;118: Brownell R, et al. Thorax. 2017;1 72: Diagnostic Process for IPF 30 Martinez, et al. Nature Reviews. 2017:3; article
11 Non-pharmacologic Care for Patients with IPF Components of Care Educate patients Refer to reliable sources Treatment of comorbid illness GERD, OSA, CAD Prescribe O2 Screen for resting/ nocturnal/exertional requirement Close monitoring of symptoms and pulmonary function Exercise Pulmonary rehabilitation 31 Comorbidities are Common in IPF Contribute to decreased quality of life May be related to the pathobiology of ILD/IPF May be more common in IPF Common comorbidities include: Cardiovascular disease (3%-68%) Gastroesophageal reflux disease (0%-94%) Obstructive sleep apnea/sleep disorders (6%-91%) Pulmonary hypertension (3%-86%) COPD (6%-67%) Lung cancer (3%-48%) 32 Raghu G. Eur Respir J. 2015;46(4) Treatment Recommendations for IPF Strong Recommendation Against Use: Anticoagulation (warfarin), Pred/Aza/NAC, ambrisentan, Imatinib Conditional Recommendation for Use: Nintedanib, pirfenidone, GERD Conditional Recommendation Against Use: NAC, macitentan, bosentan, sildenafil Raghu, et al. Am J Respir Crit Care Med 2015;192:e
12 High Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis Mortality NAC = 9% Placebo = 11% p=0.69 Demedts et al; NEJM 2005;353: PANTHER Prednisone-Azathioprine-Nacetyl cysteine: A Trial THat Evaluates Responses in IPF Diagnosis of IPF with FVC > 50%, DLCO > 30% predicted Three arms Placebo N-acetyl cysteine Pred/aza/NAC Primary Endpoint Change in FVC over 60wk Raghu et al. N Engl J Med 2012; 366: Interim Analysis with 50% data Combination n = 77, Placebo n= 78 Increased Death 8 vs 1, p=0.01 Increased Hosp 23 v 7, p<0.001 No physio/clinical benefit Termination of combination therapy at mean of 32 weeks Recommendation against use of pred/azthioprine/n-acetyl cysteine Raghu et al. N Engl J Med 2012; 366:
13 NAC Does Not Reduce FVC Decline 37 Martinez FJ, et al. N Engl J Med. 2014;370(22): Tollip (rs ) Genotype Associated with Response to N-acetyl Cysteine CC genotype HR 3.23 (95% CI 0.79, 13.16) p=0.10 CT genotype HR 0.76 (95% CI 0.27, 2.19) p=0.62 TT genotype HR 0.14 (95% CI 0.02, 0.83) p= Oldham et al. Am J Resp Crit Care Med 2015;192: Pharmacologic Management of IPF FDA approved October 15, Lederer and Martinez N Eng J Med. 2018;378:
14 Pirfenidone and Nintedanib Attenuate Loss of FVC Across Multiple Patient Subgroups Pirfenidone Nintedanib 40 Noble PW et al. Eur Respir J. 2016;47: Costabel U et al. Am J Respir Crit Care Med. 2016;193(2): RECAP Open Label Extension Study of Pirfenidone Enrolled 1,058 of the 1,334 patients from the phase 3 studies Followed September 2008 à June 2015 Common Adverse events Nausea (28%) Diarrhea (23%) Fatigue 20%) Dizziness (17%) Costabel et al. Respiration 2017;94: INPULSIS-ON Open Label Extension of Nintedanib 807 completed INPULSIS 734 enrolled INPUULSIS-ON 304 (41%) new nintedanib 31 month median exposure Crestaniet al. Lancet Resp Med 2017;94: Events/100 exposure years Prior/New nintedanib Diarrhea 60.1 / 71.2 Vomiting 7.2 / 10.8 Bleeding 8.4 / 6.7 Major Cardiovascular 3.4 / 2.4 Acute Exacerbation 5.8 /
15 Engaging in a Shared Decision-making Process Physician provides Treatment options Risks and benefits Mutually acceptable decision Patient provides Personal preferences Values and concerns Discuss the efficacy and safety of FDA-approved therapies Listen to patient s preferences and concerns Focus on symptom control and management of comorbidities Set treatment expectations Look at the option of lung transplantation 43 INJOURNEY Nintedanib with add on Pirfenidone Safety 12 week open label, 4-5 weeks run in on nintedanib 150mg/BID with randomization to placebo or pirfenidone Primary endpoint was GI adverse events 44 Vancheri C, et al. Am J Respir Crit Care Med. 2017:197 INJOURNEY Nintedanib with add on Pirfenidone Change in FVC at 12 weeks 45 Vancheri C, et al. Am J Respir Crit Care Med. 2017:197 15
16 Safety of Nintedanib added to Pirfenidone 24 week, single arm, open label study of patients on stable pirfenidone for > 16 weeks with add-on nintedanib Primary endpoint was remaining in study for 24 weeks 89 patients enrolled 69 (78%) completed 13 withdrew from AE 4 completed at lower dose 2 withdrew other reason 1 listed for lung transplant Flaherty KR, et al. Eur Resp J. 2018;52 At least 1 TEAE > 1 TEAE 88 (99%) Diarrhea 44 (49%) Nausea 41 (46%) Vomiting 21 (24%) Decreased appetite 14 (16%) Fatigue 11 (12%) Dyspepsia 8 (9%) Headache 8 (9%) Photosensitivity/Rash 7 (8%) Abdominal pain 5 (6%) 46 Dizziness 5 (6%) Gastroesophageal Reflux (GERD) in IPF GER is highly prevalent in patients with IPF Observational study (n = 204); 47% received GER medical therapy, and 5% surgical 47 Lee JS, et al. Am J Respir Crit Care Med. 2011;184: WRAP-IPF Evaluation of Laproscopic Anti-reflux Surgery in Patients with IPF and GERD Surgery favored in: Rate of FVC decline (primary) vs 0.13 Liters (p=0.28) Time to death or 10% drop FVC (p=0.038) Time to death, 10% drop FVC or Acute Exacerbation (p=0.048) Worst rank FVC analysis (p=0.017) Fewer acute exacerbations, respiratory hospitalizations, lung transplant, non-respiratory hospitalization (p=ns) 58 subjects with IPF, FVC >50% & DeMeester score of > Raghu et al. Lancet Respir Med 2018;6 16
17 Presence of Streptococcus or Staphylococcus is Associated with IPF Disease Progression 55 subjects enrolled in the COMET study Microbiome analysis of BAL fluid Disease progression = Death, Transplant, Acute Exacerbation, drop of FVC of 10% or DLCO of 15% Streptococcus p=0.009 Han, et al. Lancet Resp Med 2014:2; Staphylococcus p= Co-Trimoxazole Treatment in IPF 181 subjects with IPF randomized to co-trimoxazole vs placebo for 12 months No difference in FVC, DLCO, 6MWT, MRC dyspnea score Survival Fewer respiratory tract infections Increased nausea and rash Improved mortality in perprotocol patients (not ITT) 3/53 vs 14/65; HR 0.21 (0.06, 0.78; p=0.02) 50 Sulgina, et al. Thorax 2013:68; CLEAN-UP IPF Study Randomized trial of subjects with IPF Trimethoprim/sulfamethoxazole or doxycycline vs placebo Followed up to 36 months Primary endpoint First non-elective hospitalization or death Secondary endpoints Lung function, Patient reported outcomes NCT
18 IPF Pathobiology Lederer and Martinez N Eng J Med. 2018;378: IPF Emerging Therapeutic Targets Pentraxin 2 analogs Anti-Connective Tissue Growth Factor Anti-integrin antibodies Leukotreine antagonists Anti-LOX antibodies Protein kinase inhibitors Autotaxin-LPA pathway inhibitors PI3-kinase-mTOR pathway inhibitors Anti B-lymphocyte agents Antimicrobial agents Stem cell transplant 53 Aryal & Nathen Expert Opinion Emerging Drugs 2018;23: Members of the IPF Care Team Multidisciplinary Team of Physicians Pulmonary, Radiology, Pathology, Rheumatology, Cardiology, Thoracic Surgery, Lung Transplant Social Work Clinical Nurse Specialist Palliative Care Students/Residents/Fellows Research Coordinator Support Group 54 18
19 Impact of Delays in Evaluation at Tertiary Center on Survival in Patients with IPF <1 year 1-2 years 2-4 years >4 years Survival Lamas DJ et al. Am J Respir Crit Care Med. 2011;184(7): P for trend = Years POST-TEST QUESTIONS 57 19
20 Pre-I1: On average how much time is estimated to elapse between onset of symptoms and correct diagnosis: 1. 6 months years years Post-test ARS Question 1 4. More than 5 years 58 Post-test ARS Question 2 Pre-I2: Each of the following diagnostic tests should typically be performed in the evaluation of patients with suspected ILD except: 1. Complete history and physical exam 2. Complete pulmonary function testing including pulmonary mechanics and diffusion capacity for carbon monoxide 3. High resolution CT of the chest 4. Video assisted surgical lung biopsy 59 Post-test ARS Question 3 Pre-I3: A 64 year old male with newly diagnosed IPF returns to clinic to discuss possible therapy. Which of the following choices would be most likely to slow the decline in his lung function (FVC)? 1. Prednisone/azathioprine/N-acetyl cysteine 2. Pirfenidone or nintedanib 3. Warfarin 4. N-acetyl cysteine 5. Imatanib 60 20
21 Post-test ARS Question 4 Pre-I4: Each of the following co-morbidities are common with IPF except: 1. Cardiovascular disease 2. Gastroesophageal reflux disease 3. Obstructive sleep apnea/sleep disorders 4. Asthma 5. Pulmonary hypertension 61 Post-I5: After participating in this program, how confident are you now in your ability to educate patients with ILD on the most effective strategies to improve their outcomes? 1. Not at all confident 2. Not very confident 3. Somewhat confident 4. Pretty much confident 5. Very confident Post-test ARS Question
Progress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More information9/12/18. Emerging Challenges in Primary Care: Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis
Emerging Challenges in Primary Care: 2018 Navigating the Maze of Interstitial Lung Disease: Improving Outcomes through Early Diagnosis Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationINTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationIPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.
More informationInterstitial Lung Disease (ILD)
Interstitial Lung Disease (ILD) ILD comprises more than 130 distinct disorders Characterized by cellular proliferation, cellular infiltration, and/or fibrosis of the lung parenchyma not due to infection
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More informationUpdate on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationSummary: Key Learning Points, Clinical Strategies, and Future Directions
Summary: Key Learning Points, Clinical Strategies, and Future Directions Introduction Idiopathic pulmonary fibrosis (IPF), a peripheral lobular fibrosis of unknown cause, is a chronic, progressive lung
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Idiopathic Pulmonary Fibrosis Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Idiopathic Pulmonary Fibrosis (Esbriet /pirfenidone, Ofev /nintedanib)
More informationNintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationStrategies for Updated Treatment Options for IPF
Strategies for Updated Treatment Options for IPF Paul W. Noble, MD Vera and Paul Guerin Family Distinguished Chair in Pulmonary Medicine Professor and Chair Department of Medicine Director, Women's Guild
More informationDiagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationNew Horizons The Future of IPF and ILD
New Horizons The Future of IPF and ILD Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair, Department of Medicine University of California San Francisco
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationIPF: Epidemiologia e stato dell arte
IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic
More informationTherapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic
Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Amy Olson, MD, MSPH Associate Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationGuidelines for Diagnosis and Treatment of IPF
Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease
More informationIPF - Inquadramento clinico
IPF - Inquadramento clinico Sergio Harari Unità Operativa di Pneumologia UTIR Servizio di Fisiopat. Resp. e Emodinamica Polmonare Ospedale S. Giuseppe, Milano Clinical Classification Diffuse parenchimal
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationConflicts of Interest. Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck
Conflicts of Interest Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck The Idiopathic Interstitial Pneumonias Idiopathic pulmonary
More informationDifficulties Diagnosing Idiopathic Pulmonary Fibrosis
1. er Encuentro Entre Neumólogos y Radiólogos, Madrid, Spain, 2016, October 14th Difficulties Diagnosing Idiopathic Pulmonary Fibrosis Simon Walsh King s College Hospital Foundation Trust London, United
More informationUnpaid scientific collaborator & advisor with Veracyte, Inc.
Diagnosis and Classification of Idiopathic Interstitial Pneumonias: Role of Histopathology in the Golden Age of Consensus Jeffrey L. Myers, M.D. A. James French Professor of Diagnostic Pathology Vice Chair
More informationPresente e futuro della terapia della fibrosi polmonare idiopatica
Presente e futuro della terapia della fibrosi polmonare idiopatica Antonella Caminati U.O. di Pneumologia e Terapia Semi Intensiva Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare Osp.
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationImaging: how to recognise idiopathic pulmonary fibrosis
REVIEW IDIOPATHIC PULMONARY FIBROSIS Imaging: how to recognise idiopathic pulmonary fibrosis Anand Devaraj Affiliations: Dept of Radiology, St George s Hospital, London, UK. Correspondence: Anand Devaraj,
More informationNew Therapies and Trials in IPF
Conflict of interest disclosure I have the following real or perceived conflicts of interest that relate to this presentation: New Therapies and Trials in IPF Talmadge E. King, Jr., M.D. Julius R. Krevans
More informationIdiopathic Pulmonary Fibrosis Treatable and Not Idiopathic
Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic Brett Ley, MD University of California San Francisco CTS 1/26/18 Disclosures Speaker s bureau honorarium from Genentech (makers of pirfenidone)
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationDiagnosing ILD. What is important in 2016? Chris Grainge
Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationNINTEDANIB MEDIA BACKGROUNDER
NINTEDANIB MEDIA BACKGROUNDER 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. International treatment guidelines for IPF 1. What is nintedanib? Nintedanib (OFEV a ) is a small molecule
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More informationUsual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia Nitra and the Gangs. บทน ำและบทท ๓, ๑๐, ๑๒, ๑๓, ๑๔, ๑๕, ๑๗ Usual Interstitial Pneumonia (UIP) Most common & basic pathologic pattern
More informationThe radiological differential diagnosis of the UIP pattern
5th International Conference on Idiopathic Pulmonary Fibrosis, Modena, 2015, June 12th The radiological differential diagnosis of the UIP pattern Simon Walsh King s College Hospital Foundation Trust London,
More informationOFEV MEDIA BACKGROUNDER
OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small
More informationPNEUMOLOGIA 2018 Milano, giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE. Il futuro dell IPF: dove stiamo andando. Carlo Albera
PNEUMOLOGIA 2018 Milano, 14 16 giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE Il futuro dell : dove stiamo andando Carlo Albera Università di Torino, Scuola di Medicina Dipartimento di Scienze Cliniche e
More informationIdiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping
Idiopathic Pulmonary Fibrosis: The Importance of Qualitative and Quantitative Phenotyping K. R. Flaherty Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor,
More informationDaria Manos RSNA 2016 RC 401. https://medicine.dal.ca/departments/depar tment-sites/radiology/contact/faculty/dariamanos.html
Daria Manos RSNA 2016 RC 401 https://medicine.dal.ca/departments/depar tment-sites/radiology/contact/faculty/dariamanos.html STEP1: Is this fibrotic lung disease? STEP 2: Is this a UIP pattern? If yes:
More informationWim Wuyts. Treatment of idiopathic interstitial pneumonias. March 12 th Interstitial lung diseases state of the art.
nterstitial ungdiseases euven Department of pneumology Unit for interstitial lung diseases University Hospitals Leuven March 12 th 2015 Interstitial lung diseases state of the art Treatment of idiopathic
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationManish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
More informationUIP Possibile e Probabile
UIP Possibile e Probabile Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale San Giuseppe - Milano Current definition of IPF IPF is a distinct type
More informationLines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationThoracic lung involvement in rheumatoid arthritis: Findings on HRCT
Thoracic lung involvement in rheumatoid arthritis: Findings on HRCT Poster No.: C-2488 Congress: ECR 2015 Type: Educational Exhibit Authors: R. E. Correa Soto, M. J. Martín Sánchez, J. M. Fernandez 1 1
More informationExperience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina
ORIGINAL 131 RAMR 2017;2:131-135 ISSN 1852-236X Correspondence Gabriela Tabaj gabrielatabaj@gmail.com Received: 11.15.2016 Accepted: 02.03.2017 Experience with the Compassionate Use Program of nintedanib
More informationDisclosures. IPF Medications: Practical Experience. Prednisone, Azathioprine, N acyetylcysteine. Case 1. Brett Ley, MD, MAS Assistant Professor, UCSF
IPF Medications: Practical Experience Disclosures Received speakers bureau honorarium from Roche/Genentech (makers of pirfenidone). Brett Ley, MD, MAS Assistant Professor, UCSF 67 y/o man 1 year cough
More informationCurrent diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM
Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University
More informationNAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis
NAVIGATING the NEW ERA in IPF: Idiopathic Pulmonary Fibrosis Mark J Rumbak, MD Division Director Pulmonary, Critical Care and Sleep Medicine Morsani College of Medicine University of South Florida, Tampa
More informationAn earlier and more confident diagnosis of idiopathic pulmonary fibrosis
Eur Respir Rev 2012; 21: 124, 141 146 DOI: 10.1183/09059180.00000812 CopyrightßERS 2012 REVIEW: IPF An earlier and more confident diagnosis of idiopathic pulmonary fibrosis Roland M. du Bois ABSTRACT:
More informationPatient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationINVITED REVIEW SERIES: PULMONARY FIBROSIS SERIES EDITORS: MARTIN KOLB AND GERARD COX
INVITED REVIEW SERIES: PULMONARY FIBROSIS SERIES EDITORS: MARTIN KOLB AND GERARD COX Diagnosing fibrotic lung disease: When is high-resolution computed tomography sufficient to make a diagnosis of idiopathic
More informationRadiologic pathologic discordance in biopsy-proven usual interstitial pneumonia
ERJ Express. Published on February 25, 2016 as doi: 10.1183/13993003.01680-2015 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Radiologic pathologic discordance in biopsy-proven usual interstitial pneumonia
More informationIdiopathic Pulmonary of Care
Chapter 6.1 Living Medical etextbook A Digital Tool at the Point of Care From Projects In Knowledge Pulmonology Idiopathic Pulmonary Fibrosis @Point of Care IPF Case Study: Typical Presentation, Role of
More informationIdiopathic pulmonary fibrosis
Pharmacologic Treatments for Idiopathic Pulmonary Fibrosis This chronic disease has historically lacked an effective treatment option, but the FDA recently approved two: pirfenidone and nintedanib. This
More informationRole of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study
36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E
More informationManagement of Idiopathic Pulmonary Fibrosis
Management of Idiopathic Pulmonary Fibrosis Robert Hallowell, M.D. December 22, 2015 Disclosures No financial disclosures What causes IPF? +? VEGF-R Airspace lining TNFa Fibrocytes PDGF Fibroblasts IL-1
More informationCase 1: Question. 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule
HRCT WORK SHOP Case 1 Case 1: Question 1.1 What is the main pattern of this HRCT? 1. Intralobular line 2. Groundglass opacity 3. Perilymphatic nodule Case 1: Question 1.2 What is the diagnosis? 1. Hypersensitivity
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationIDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management
IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management An ATS Pocket Publication This publication was produced in collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. GUIDELINES
More informationCriteria for confident HRCT diagnosis of usual interstitial pneumonia (UIP)
Criteria for confident HRCT diagnosis of usual interstitial pneumonia (UIP) Assem El Essawy (1) & Amr A. Nassef (٢) Abstract Identification of interstitial pneumonia (IP) was mainly based on histological
More informationChallenges in the Diagnosis of Interstitial Lung Disease
Challenges in the Diagnosis of Interstitial Lung Disease Kirk D. Jones, MD UCSF Dept. of Pathology kirk.jones@ucsf.edu Overview New Classification of IIP Prior classification Modifications for new classification
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Idiopathic Pulmonary Fibrosis Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective
More informationFocus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis, and Treatment
Focus on Idiopathic Pulmonary Fibrosis: Advancing Approaches to Diagnosis, Prognosis, and Treatment Discussion Points Diagnosis Prognosis Therapy Imminent future 2 Discussion Points (con't) Diagnosis Overview
More informationCryptogenic Organizing Pneumonia Diagnosis Approach Based on a Clinical-Radiologic-Pathologic Consensus
Cryptogenic Organizing Pneumonia Diagnosis Approach Based on a Clinical-Radiologic-Pathologic Consensus Poster No.: C-1622 Congress: ECR 2012 Type: Scientific Exhibit Authors: C. Cordero Lares, E. Zorita
More informationCase 1 : Question. 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random
Interesting case Case 1 Case 1 : Question 1.1 What is the intralobular distribution? 1. Centrilobular 2. Perilymphatic 3. Random Case 1: Answer 1.1 What is the intralobular distribution? 1. Centrilobular
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationDr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham
Dr. Tracy Luckhardt Division of Pulmonary, Allergy and Critical Care Medicine University of Alabama at Birmingham Types of Questions you Will Be Asked Rhetorical Participatory Disclosure of Relevant Financial
More informationLung Allograft Dysfunction
Lung Allograft Dysfunction Carlos S. Restrepo M.D. Ameya Baxi M.D. Department of Radiology University of Texas Health San Antonio Disclaimer: We do not have any conflict of interest or financial gain to
More informationThe Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page
The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page 1135-1140 Role of High Resolution Computed Tomography in Diagnosis of Interstitial Lung Diseases in Patients with Collagen Diseases
More informationPFF HEALTH CARE PROFESSIONAL WEBINAR SERIES. Welcome!
PFF HEALTH CARE PROFESSIONAL WEBINAR SERIES Welcome! AGENDA TOPICS Welcome & Introduction Dr. Gregory Cosgrove, MD Chief Medical Officer Pulmonary Fibrosis Foundation PFF Resources Dolly Kervitsky, RCP,
More informationIPF : Dalla Diagnosi alla Terapia
IV Forum di Pneumologia Interventistica Bologna 5-6 Giugno 2015 IPF : Dalla Diagnosi alla Terapia Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale
More informationManagement of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures
Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board
More informationPerspectives ILD Diagnosis and Treatment in 5-10 years
Perspectives ILD Diagnosis and Treatment in 5-10 years Brett Ley, MD Department of Medicine The (Near) Future of ILD Diagnosis and Treatment 1. Combination therapy for Idiopathic Pulmonary Fibrosis 2.
More informationEvaluating New Treatment Options
Evaluating New Treatment Options Steven D. Nathan, MD Clinical Practice Guideline Changes 211 ATS/ERS/JRS/ALAT Recommendations Treatment of IPF combines nonpharmacologic and pharmacologic strategies, and
More informationCT in Idiopathic Pulmonary Fibrosis: Diagnosis and Beyond
Cardiopulmonary Imaging Review Gruden CT of Idiopathic Pulmonary Fibrosis Cardiopulmonary Imaging Review James F. Gruden 1 Gruden JF FOCUS ON: Keywords: CT, diagnosis, high-resolution CT, idiopathic pulmonary
More informationOctober 30, The Westin Princeton at Forrestal Village 201 Village Boulevard Princeton, NJ Marilyn Glassberg Csete, MD FACP, FCCP
October 3, 215 The Westin Princeton at Forrestal Village 21 Village Boulevard Princeton, NJ 854 Marilyn Glassberg Csete, MD FACP, FCCP Professor of Medicine, Surgery, and Pediatrics at the University of
More informationTriple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis
Editorial Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Tomoo Kishaba Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma City, Okinawa, Japan
More informationINHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)
THE INCREASE STUDY INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) Peter Smith, PharmD Senior Director Product Development, United Therapeutics Corporation 2 SAFE
More informationESBRIET (pirfenidone) oral capsule and oral tablet OFEV (nintedanib) oral capsule
OFEV (nintedanib) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More information